AstraZeneca reveals first clinical data for bispecific T cell engager from TeneoTwo buyout

The company’s stock has dropped by 15% after the Phase II trial data was announced. Image credit: Shutterstock / pathdoc Vertex Pharmaceuticals’s non-opioid-based pain therapy

The Eu­ro­pean Com­mis­sion on Thurs­day an­nounced a first for its reg­u­la­tion of the phar­ma in­dus­try: It’s fin­ing five phar­ma com­pa­nies — Al­ka­loids of Aus­tralia, Al­ka­loids